Khaled Osman, DO
General Practice · Brooklyn, NYNPI 1518131846
Payments from drug & device makers
Across 213 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$488
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$391
- Lilly USA, LLC$371
- GSK$338
- Novo Nordisk$325
- Abbott$290
- plus $3K from 25 others
What the payments were for
- Food & beverage$4,57997%
- Education$1383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $488 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $391 |
| Lilly USA, LLC | 15 | $371 |
| GSK | 16 | $338 |
| Novo Nordisk | 15 | $325 |
| Abbott | 11 | $290 |
| Merck | 12 | $257 |
| AstraZeneca | 13 | $255 |
| Ardelyx, Inc. | 9 | $215 |
| Pfizer | 9 | $206 |
| Exact Sciences | 11 | $184 |
| Novartis | 7 | $178 |
| Phathom Pharmaceuticals, Inc. | 8 | $173 |
| Optinose US, Inc. | 7 | $164 |
| Shield Therapeutics Inc | 5 | $125 |
| Xeris Pharmaceuticals, Inc. | 6 | $121 |
| Amgen(2 entities) | 5 | $105 |
| Intra-sana Laboratories | 3 | $78 |
| Amarin Pharma, Inc. | 3 | $49 |
| Redhill Biopharma Inc. | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| AbbVie | 2 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Phadia US Inc. | 2 | $33 |
| Renalytix AI, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
How this compares
$4,717 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 303 | $588,790 |
| Diclofenac Sodium | 545 | $511,199 |
| Diclofenac Potassium | 104 | $245,741 |
| MounjaroTirzepatide | 157 | $184,387 |
| OzempicSemaglutide | 161 | $169,400 |
| JanumetSitagliptin Phos/Metformin Hcl | 212 | $134,728 |
| JanuviaSitagliptin Phosphate | 166 | $117,724 |
| Dihydroergotamine Mesylate | 81 | $114,561 |
| TrulicityDulaglutide | 104 | $111,842 |
| OpzeluraRuxolitinib Phosphate | 31 | $108,684 |
| LinzessLinaclotide | 169 | $104,795 |
| FarxigaDapagliflozin Propanediol | 118 | $93,139 |
| Lactulose | 30 | $92,824 |
| MeloxicamMeloxicam, Submicronized | 83 | $82,427 |
| Methocarbamol | 37 | $78,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $371 | $296,229261 claims |
| MerckJanumet, Januvia | $257 | $252,452378 claims |
| Novo NordiskOzempic, Rybelsus | $325 | $193,518183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $255 | $129,683174 claims |
| AbbVieLinzess | $40 | $104,795169 claims |
| Boehringer IngelheimJardiance, Jentadueto | $38 | $71,62587 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $338 | $52,32689 claims |
| PfizerNurtec Odt, Eliquis | $206 | $39,61639 claims |
| AmgenProlia | $105 | $37,12223 claims |
| Astellas Pharma US IncMyrbetriq | $488 | $20,02346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in Brooklyn
- Stuart DitchekBrooklyn$171K
- Anthony RamirezBrooklyn$114K
- Isaac TawilBrooklyn$60K
- Jerome CantorBrooklyn$32K
- Margarita DegtyarevaBrooklyn$14K
- Mark HochmanHicksville$5.1M
- Sarah AtkinsonRochester$4.2M
- Michael MashaalRoslyn$1.9M
- David RiceEast Amherst$1.2M
- Alejandra Gonzalez-DuarteNew York$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.